ArticleFuture science OA2015
Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease.
Article in Future science OA, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT-TOPIC trial after 1-year follow-up.United European gastroenterology journal · 2022Trial
- Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease.Alimentary pharmacology & therapeutics · 2021Trial
- Viewpoint: The Use of Antimycobacterial (Anti-MAP) Therapies in the Treatment of Active Luminal Crohn's Disease.JGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Hyperbaric Oxygen Therapy in the Management of Refractory Perianal Crohn's Disease.Journal of clinical medicine · 2025Article
- A Guide Through the Tunnel: Updates in the Approach to Classification and Management of Perianal Fistulizing Crohn's Disease.Current gastroenterology reports · 2025Review
- Hyperbaric Oxygen Therapy in the Treatment of Crohn's Disease.Healthcare (Basel, Switzerland) · 2025Article
- The new insights of hyperbaric oxygen therapy: focus on inflammatory bowel disease.Precision clinical medicine · 2024Review
- The effects of hyperbaric treatment on perianal fistula activity in patients with Crohn's disease.Przeglad gastroenterologiczny · 2024Article
- Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management.Therapeutic advances in gastroenterology · 2024Review
- Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.Clinical and experimental gastroenterology · 2024Review
- Vaccination therapy for inflammatory bowel disease.Human vaccines & immunotherapeutics · 2023Review
- Review
- Article
- Design, development, and evaluation of a registry system for hyperbaric oxygen therapy: A methodological study.Health science reports · 2022Article
- Hyperbaric Oxygen Therapy in Systemic Inflammatory Response Syndrome.Veterinary sciences · 2022Article
- Article
- Profound remission in Crohn's disease requiring no further treatment for 3-23 years: a case series.Gut pathogens · 2020Article
- Welcome to volume 2 ofFuture science OA · 2016Article
- The role of hyperbaric oxygen therapy in inflammatory bowel disease: a narrative review.Medical gas researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFistulizing Crohn's disease (CD) presents a therapeutic challenge as fistulae are notoriously difficult to heal.
aimWe evaluated healing of CD fistula(e) using a novel combination therapy. STUDY: Nine consecutive patients who failed to heal fistulae on conventional treatment including anti-TNF, were treated with at least three doses of infliximab, 18-30 courses of hyperbaric oxygen therapy and anti-MAP antibiotics comprising rifabutin, clarithromycin and clofazimine.
resultsAll patients achieved complete healing of fistulae by 6-28 weeks and follow-up for mean 18 months.
conclusionCombining infliximab, hyperbaric oxygen therapy and anti-MAP, seems to enable healing of recalcitrant fistulae and although a small case series, all nine patients achieved complete healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.